Lexaria Bioscience Corp. LEXX
NASDAQ
| 05/31/2026 | 02/28/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.66% | 10.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 35.46% | -6.46% | |||
| Operating Income | -37.32% | 7.73% | |||
| Income Before Tax | -37.44% | 9.12% | |||
| Income Tax Expenses | -100.00% | 44.44% | |||
| Earnings from Continuing Operations | -37.19% | 9.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -35.71% | 12.00% | |||
| Net Income | -37.32% | 9.09% | |||
| EBIT | -37.32% | 7.73% | |||
| EBITDA | -37.81% | 7.97% | |||
| EPS Basic | -35.32% | 20.50% | |||
| Normalized Basic EPS | -35.64% | 19.45% | |||
| EPS Diluted | -35.32% | 20.50% | |||
| Normalized Diluted EPS | -35.64% | 19.45% | |||
| Average Basic Shares Outstanding | 1.48% | 14.35% | |||
| Average Diluted Shares Outstanding | 1.48% | 14.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||